

News Article downloaded from - <http://www.bioportfolio.com> on Friday, November 27, 2009  
Read [Two New Studies Report Increased Survival Rates in Tamiflu\(R\)-Treated Patients with Avian Flu \(H5N1\) and Severe Seasonal Flu](http://www.bioportfolio.com/news/Two_New_Studies_Report_Increased_Survival_Rates.html) on BioPortfolio.com  
([http://www.bioportfolio.com/news/Two\\_New\\_Studies\\_Report\\_Increased\\_Survival\\_Rates.html](http://www.bioportfolio.com/news/Two_New_Studies_Report_Increased_Survival_Rates.html))

## Two New Studies Report Increased Survival Rates in Tamiflu(R)-Treated Patients with Avian Flu (H5N1) and Severe Seasonal Flu

**Sunday 13th of September 2009 14:15**

-- Emergence and Evolution of Influenza A (H1N1) Viruses with H274Y and Associated Mutations (Poster 561) - Sunday, September 13, 2009, 11:15 a.m. - 1:15 p.m., Hall B.

Abstracts are available at [www.icaac.org](http://www.icaac.org).

### *About Tamiflu*

Tamiflu, co-developed by Gilead Sciences, Inc., based in Foster City, CA, is indicated for the treatment of uncomplicated influenza caused by viruses types A and B in patients one year and older who have had flu symptoms for no more than two days. Tamiflu is also indicated for the prevention of influenza in patients one year and older. Tamiflu is not a substitute for annual early vaccination as recommended by the CDC. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Tamiflu.

In post-marketing experience, rare cases of anaphylaxis and serious skin reactions have been reported. There have been post-marketing reports (mostly from Japan) of self-injury and delirium with the use of Tamiflu in patients with influenza. The reports were primarily among children. The relative contribution of the drug to these events is not known. Patients with influenza should be closely monitored for signs of abnormal behavior throughout the treatment period.

The most frequently reported adverse events in clinical studies were nausea, vomiting, and diarrhea. Tamiflu is available for the treatment of influenza in more than 80 countries worldwide. Prescribing information for Tamiflu is available at [www.rocheusa.com/products/tamiflu](http://www.rocheusa.com/products/tamiflu).

### *About Roche*

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly

differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: [www.roche.com](http://www.roche.com).

All trademarks used or mentioned in this release are protected by law.

i) <http://content.nejm.org/cgi/content/full/358/3/261>,

<http://www.thelancet.com/journals/lancet/article/PIIS0140673608611253/abstract>

ii) Toovey, S. Avex Avian Influenza Expert Group. First results from an avian influenza case registry. Oral presentation at [Interscience Conference on Antimicrobial Agents and Chemotherapy](#) (ICAAC) 2009. Abstract V-533, 9/13/2009

iii) Lee, N *et al.* Outcomes of adults hospitalised with influenza 2007-2008. Poster presented at [Interscience Conference on Antimicrobial Agents and Chemotherapy](#) (ICAAC) 2009. Abstract V-1074k, 9/13/2009

SOURCE Roche

Via PR Newswire - PRNewswire.co.uk

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

